View Press Releases
Precision NanoSystems offers ground-breaking transfection technology for primary cells
VANCOUVER, BC, CANADA - Mar 2, 2017 - Precision NanoSystems is helping scientists to push the boundaries of neuroscience research with a range of efficient and easy-to-use primary cell transfection kits. Combining user-friendly NanoAssemblr microfluidics systems with advanced nanoparticle technology, the company has developed the Neuro9, Astro9 and iNeuro9 non-viral gene transfection kits to allow rapid and easy knockdown or expression of genes in primary cells, both in vitro and in vivo.
Precision NanoSystems innovative transfection kits are optimized for non-viral delivery of short interfering RNA (siRNA), messenger RNA (mRNA) or plasmid DNA (pDNA) into various neural cell types, such as neurons, astrocytes and iPS-derived neurons. This technology offers transfection efficiencies of up to 95 percent with no observed toxicity by taking advantage of an endogenous pathway to deliver the nucleic acid payload. Combined with the companys NanoAssemblr microfluidic technology, the kits make it fast and easy to reap the benefits of ground-breaking transfection technology.
Each kit includes all the reagents required to generate nanoparticles using the NanoAssemblr systems, and is available for either in vitro or in vivo applications. This proven technology ensures rapid, high quality and reproducible results with minimal user training, and has already become widely established in the drug formulation field.
To learn more about Precision NanoSystems transfection kits or arrange a demo, visit www.precisionnanosystems.com/transfectionreagents